Cantargia gears up with new CEO and substantial capital injection
Cantargia, a private biopharmaceutical company developing therapeutics for the treatment of leukemia, announces that Dr. Göran Forsberg will take over the CEO position Furthermore, the company has decided to issue new shares corresponding to 20 MSEK.Cantargia continues to develop successfully and is happy to announce that Göran Forsberg has been engaged to lead the company to take it into the next important development steps. In addition the long term financial strategy is followed and the company will issue shares corresponding to 20 MSEK directed to the owners of its main shareholder, LU
